Public Health
-

Abstract: Globally, infectious diseases are emerging at an increasing rate. Vector-borne diseases in particular present one of the biggest threats to public health globally. Many of these diseases are zoonotic, meaning they cycle in animal populations but can spillover to infect humans. As a result, risk to humans of acquiring a zoonotic or vector-borne disease largely depends on the distribution and abundance of the reservoir hosts—the species of animals that pathogens naturally infect—as well as of the vector species. The ecology of many reservoir hosts and vectors is rapidly changing due to global change, which will fundamentally alter human disease risk in as yet unforeseen ways. In this talk, I will present and discuss three lines of research aimed at identifying drivers of disease emergence and risk at multiple spatial scales including 1) the ecological and environmental drivers of Lyme disease in California, 2) the roles of human behavior and land use in driving human Lyme disease in the northeastern US, and 3) effects of deforestation, land use policy and socio-ecological feedbacks in driving malaria in the Brazilian Amazon.

About the Speaker: Andrew MacDonald is a disease ecologist and a National Science Foundation Postdoctoral Fellow in Biology at Stanford University. He received his PhD from the Department of Ecology, Evolution and Marine Biology at the University of California, Santa Barbara in September 2016. His dissertation focused on the effect of land use and environmental change on tick-borne disease risk in California and the northeastern US. His current work focuses on coupled natural-human system feedbacks and land use change as drivers of mosquito-borne disease, with a focus on malaria in the Amazon basin.

Encina Hall, 2nd floor

CISAC
Seminars
-

Abstract: The interactions between biological and cultural processes are critical determinants of human health. Successful public health programs must therefore be based on a synthesis of biological and anthropological research. By disentangling the impacts of behavior and biology on human health, we can update health care objectives and practices. Human movements and shifts in settlements across short and long time scales can result in misallocated health care resources and inefficient response to crises. I develop methods to quantify changing human population sizes and distributions to improve resource allocation in both routine health care settings and crisis response. This ranges from assessing health care system capacity for stable populations to outbreak control through vaccination and rapid response following population-scale disruptions due to natural disasters or political instability. This approach is also valuable in informing predictive mathematical models of human interactions and demographics to provide insight into a broader spectrum of human health issues. Here, I demonstrate these concepts specifically for the transmission and prevention of infectious diseases and access to health care in low-income settings ranging from rural Africa to urban America. 

 

About the Speaker: Nita Bharti is a Branco Weiss Society in Science fellow with an interdisciplinary background in Biology (PhD) and Anthropology (MA). She is a visiting scholar at Stanford’s Woods Institute of the Environment with a research associate appointment in the Biology Department and Center for Infectious Disease Dynamics at Penn State University. Her research integrates methods across social and natural sciences to identify and solve problems in human health, often in low-income settings. In addition to academic researchers across a wide variety of disciplines, her collaborators frequently include outreach and non-profit organizations as well as local authorities on public health and safety.

Nita Bharti Stanford Woods Institute for the Environment
Seminars
-

Abstract: The Cold War rivalry between the United States and the Soviet Union lasted for much of the second half of the 20th Century. While the superpowers never engaged directly in full-scale armed combat, a nuclear arms race became the centerpiece of a doctrine of mutually assured destruction, and prompted a mass production of plutonium, and the designing, building, and testing of large numbers of nuclear weapons. In more than 50 years of operation, the Cold War battlefields created over 100 metric tons of plutonium, produced tens of thousands of nuclear warheads, oversaw more than 1000 detonations, and left behind a legacy of contaminated facilities, soils, and ground water.  

The extent of long-term adverse health effects will depend on the mobility of plutonium and other actinides in the environment and on our ability to develop cost-effective scientific methods of removing or isolating actinides from the environment. Studying the complex chemistry of plutonium and the actinides in the environment is one of the most important technological challenges, and one of the greatest scientific challenges in actinide science today.

I will summarize our current understanding of actinide chemistry in the environment, and how that understanding was used in the decontamination and decommissioning of the Rocky Flats Site, where plutonium triggers for U.S. nuclear weapons were manufactured. At Rocky Flats, synchrotron radiation measurements made at the Stanford Synchrotron Radiation Laboratory were developed into a science-­based decision-­making tool that saved billions of dollars by focusing Site-­directed efforts in the correct  areas, and aided the most extensive cleanup in the history of Superfund legislation to finish one year ahead of schedule, ultimately resulting in billions of dollars in taxpayer savings.

 

About the Speaker: David L. Clark received a B.S. in chemistry in 1982 from the University of Washington, and a Ph.D. in inorganic chemistry in 1986 from Indiana University. His thesis work received the American Chemical Society’s Nobel Laureate Signature Award for the best chemistry Ph.D. thesis in the United States. Clark was a postdoctoral fellow at the University of Oxford before joining Los Alamos National Laboratory as a J. Robert Oppenheimer Fellow in 1988. He became a Technical Staff Member in the Isotope and Nuclear Chemistry Division in 1989. Since then he has held various leadership positions at the Laboratory, including program management for nuclear weapons and Office of Science programs, and Director of the Glenn T. Seaborg Institute for Transactinium Science between 1997-2009. He has served the DOE as a technical advisor for environmental stewardship including the Rocky Flats cleanup and closure (1995-2005), closure of High Level Waste tanks at the Savannah River Site (2011), and as a technical advisor to the DOE High Level Waste Corporate Board (2009-2011). He is currently the Program Director for the National Security Education Center at Los Alamos, a Fellow of the American Association for the Advancement of Science, a Laboratory Fellow, and Leader of the Plutonium Science and Research Strategy for Los Alamos. His research interests are in the molecular and electronic structure of actinide materials, applications of synchrotron radiation to actinide science, behavior of actinide and fission products in the environment, and in the aging effects of nuclear weapons materials. He is an international authority on the chemistry and physics of plutonium, and has published over 150 peer-reviewed publications, encyclopedia and book chapters. 

Actinide Chemistry and The Battlefields of the Cold War
Download pdf

Encina Hall (2nd floor)

David L. Clark Laboratory Fellow and Program Director, National Security Education Center, Speaker Los Alamos National Laboratory
Seminars
News Type
Q&As
Date
Paragraphs

For 14 years, Mariano-Florentino Cuéllar has been a tireless Stanford professor who has strengthened the fabric of university’s interdisciplinary nature. Joining the faculty at Stanford Law School in 2001, Cuéllar soon found a second home for himself at the Freeman Spogli for International Studies. He held various leadership roles throughout the institute for several years – including serving as co-director of the Center for International Security and Cooperation. He took the helm of FSI as the institute’s director in 2013, and oversaw a tremendous expansion of faculty, research activity and student engagement. 

An expert in administrative law, criminal law, international law, and executive power and legislation, Cuéllar is now taking on a new role. He leaves Stanford this month to serve as justice of the California Supreme Court and will be succeeded at FSI by Michael McFaul on Jan. 5.

 As the academic quarter comes to a close, Cuéllar took some time to discuss his achievements at FSI and the institute’s role on campus. And his 2014 Annual Letter and Report can be read here.

You’ve had an active 20 months as FSI’s director. But what do you feel are your major accomplishments? 

We started with a superb faculty and made it even stronger. We hired six new faculty members in areas ranging from health and drug policy to nuclear security to governance. We also strengthened our capacity to generate rigorous research on key global issues, including nuclear security, global poverty, cybersecurity, and health policy. Second, we developed our focus on teaching and education. Our new International Policy Implementation Lab brings faculty and students together to work on applied projects, like reducing air pollution in Bangladesh, and improving opportunities for rural schoolchildren in China.  We renewed FSI's focus on the Ford Dorsey Program in International Policy Studies, adding faculty and fellowships, and launched a new Stanford Global Student Fellows program to give Stanford students global experiences through research opportunities.   Third, we bolstered FSI's core infrastructure to support research and education, by improving the Institute's financial position and moving forward with plans to enhance the Encina complex that houses FSI.

Finally, we forged strong partnerships with critical allies across campus. The Graduate School of Business is our partner on a campus-wide Global Development and Poverty Initiative supporting new research to mitigate global poverty.  We've also worked with the Law School and the School of Engineering to help launch the new Stanford Cyber Initiative with $15 million in funding from the Hewlett Foundation. We are engaging more faculty with new health policy working groups launched with the School of Medicine and an international and comparative education venture with the Graduate School of Education. 

Those partnerships speak very strongly to the interdisciplinary nature of Stanford and FSI. How do these relationships reflect FSI's goals?

The genius of Stanford has been its investment in interdisciplinary institutions. FSI is one of the largest. We should be judged not only by what we do within our four walls, but by what activity we catalyze and support across campus. With the business school, we've launched the initiative to support research on global poverty across the university. This is a part of the SEED initiative of the business school and it is very complementary to our priorities on researching and understanding global poverty and how to alleviate. It's brought together researchers from the business school, from FSI, from the medical school, and from the economics department.  

Another example would be our health policy working groups with the School of Medicine. Here, we're leveraging FSI’s Center for Health Policy, which is a great joint venture and allows us to convene people who are interested in the implementation of healthcare reforms and compare the perspective and on why lifesaving interventions are not implemented in developing countries and how we can better manage biosecurity risks. These working groups are a forum for people to understand each other's research agendas, to collaborate on seeking funding and to engage students. 

I could tell a similar story about our Mexico Initiative.  We organize these groups so that they cut across generations of scholars so that they engage people who are experienced researchers but also new fellows, who are developing their own agenda for their careers. Sometimes it takes resources, sometimes it takes the engagement of people, but often what we've found at FSI is that by working together with some of our partners across the university, we have a more lasting impact.

Looking at a growing spectrum of global challenges, where would you like to see FSI increase its attention? 

FSI's faculty, students, staff, and space represent a unique resource to engage Stanford in taking on challenges like global hunger, infectious disease, forced migration, and weak institutions.  The  key breakthrough for FSI has been growing from its roots in international relations, geopolitics, and security to focusing on shared global challenges, of which four are at the core of our work: security, governance, international development, and  health. 

These issues cross borders. They are not the concern of any one country. 

Geopolitics remain important to the institute, and some critical and important work is going on at the Center for International Security and Cooperation to help us manage the threat of nuclear proliferation, for example. But even nuclear proliferation is an example of how the transnational issues cut across the international divide. Norms about law, the capacity of transnational criminal networks, smuggling rings, the use of information technology, cybersecurity threats – all of these factors can affect even a traditional geopolitical issue like nuclear proliferation. 

So I can see a research and education agenda focused on evolving transnational pressures that will affect humanity in years to come. How a child fares when she is growing up in Africa will depend at least as much on these shared global challenges involving hunger and poverty, health, security, the role of information technology and humanity as they will on traditional relations between governments, for instance. 

What are some concrete achievements that demonstrate how FSI has helped create an environment for policy decisions to be better understood and implemented?

We forged a productive collaboration with the U.N. High Commissioner for Refugees through a project on refugee settlements that convened architects, Stanford researchers, students and experienced humanitarian responders to improve the design of settlements that house refugees and are supposed to meet their human needs. That is now an ongoing effort at the UN Refugee Agency, which has also benefited from collaboration with us on data visualization and internship for Stanford students. 

Our faculty and fellows continue the Institute's longstanding research to improve security and educate policymakers. We sometimes play a role in Track II diplomacy on sensitive issues involving global security – including in South Asia and Northeast Asia.  Together with Hoover, We convened a first-ever cyber bootcamp to help legislative staff understand the Internet and its vulnerabilities. We have researchers who are in regular contact with policymakers working on understanding how governance failures can affect the world's ability to meet pressing health challenges, including infectious diseases, such as Ebola.

On issues of economic policy and development, our faculty convened a summit of Japanese prefectural officials work with the private sector to understand strategies to develop the Japanese economy.  

And we continued educating the next generation of leaders on global issues through the Draper Hills summer fellows program and our honors programs in security and in democracy and the rule of law. 

How do you see FSI’s role as one of Stanford’s independent laboratories?

It's important to recognize that FSI's growth comes at particularly interesting time in the history of higher education – where universities are under pressure, where the question of how best to advance human knowledge is a very hotly debated question, where universities are diverging from each other in some ways and where we all have to ask ourselves how best to be faithful to our mission but to innovate. And in that respect, FSI is a laboratory. It is an experimental venture that can help us to understand how a university like Stanford can organize itself to advance the mission of many units, that's the partnership point, but to do so in a somewhat different way with a deep engagement to practicality and to the current challenges facing the world without abandoning a similarly deep commitment to theory, empirical investigation, and rigorous scholarship.

What have you learned from your time at Stanford and as director of FSI that will inform and influence how you approach your role on the state’s highest court?

Universities play an essential role in human wellbeing because they help us advance knowledge and prepare leaders for a difficult world. To do this, universities need to be islands of integrity, they need to be engaged enough with the outside world to understand it but removed enough from it to keep to the special rules that are necessary to advance the university's mission. 

Some of these challenges are also reflected in the role of courts. They also need to be islands of integrity in a tumultuous world, and they require fidelity to high standards to protect the rights of the public and to implement laws fairly and equally.  

This takes constant vigilance, commitment to principle, and a practical understanding of how the world works. It takes a combination of humility and determination. It requires listening carefully, it requires being decisive and it requires understanding that when it's part of a journey that allows for discovery but also requires deep understanding of the past.

Hero Image
All News button
1
Authors
By Beth Duff-Brown
News Type
Q&As
Date
Paragraphs

(Updated Nov. 7, 2014)

The Centers for Disease Control and Prevention reported on Nov. 4 that the death toll from the Ebola outbreak in West Africa has risen to above 4,960 and that an estimated 8,168 people, mostly in Liberia, Sierra Leone and Guinea, have contracted the virus since March. It is the largest and most severe outbreak of the Ebola virus since it was first detected four decades ago. All but nine of the deaths were in those three countries; eight were in Nigeria and one patient died in the United States.

The CDC in October proclaimed that in the worst-case scenario, Sierra Leone and Liberia could have 1.4 million cases by Jan. 20, 2015, if the disease keeps spreading without immediate and immense intervention to contain the virus.

Two American aid workers infected with Ebola while working in West Africa were transported to a containment unit at Emory University in Atlanta for treatment, raising public fears about international spread of the highly virulent virus that has no known cure. The two were released from the hospital after being the first humans to receive an experimental Ebola drug called ZMapp. Another man who recently helped an Ebola victim in Liberia traveled to Texas and died in a Dallas hospital. Two of the nurses who treated him caught the virus as well, but have been released from the hospital. Some states have struggled with the moral 

We ask CISAC biosecurity experts David Relman and Megan Palmer to answer several questions about Ebola and the public health concerns and policy implications. Relman is the co-director of the Center for International Security and Cooperation who has served on several federal committees investigating biosecurity matters. He is the Thomas C. and Joan M. Merigan Professor in the Departments of Medicine and of Microbiology and Immunology at Stanford University School of Medicine, and Past-President of the Infectious Diseases Society of America.

Palmer is the William J. Perry Fellow in International Security at CISAC and a Researcher at the UC Berkeley Center for Quantitative Biosciences (QB3), and served as Deputy Director of Policy & Practices for the Multi-University NSF Synthetic Biology Engineering Research Center (SynBERC).

The two of them have answered the questions together.

What is Ebola and how dangerous is it compared to other diseases?

Ebola is an acute viral infectious disease, often associated with severe hemorrhagic fever. While initial symptoms are flu-like, they can rapidly progress, and include vomiting, reduced ability to regulate immune responses and other physiological processes, sometimes leading to internal and external bleeding. The disease has an incubation period that can last up to 21 days, but patients typically become ill four to nine days after infection, and die about seven to ten days later. Fatality rates for the current Ebola outbreak are nearing 60% (according to the CDC), while past outbreaks in the Republic of Congo have seen rates as high as 90%. This outbreak to date has resulted in nearly 1,000 deaths, more than any previous Ebola outbreak.

Ebola virus is believed to reside in animals such as fruit bats where it does not cause disease, but is then transmitted to and among humans and other primates, in whom disease typically does occur. The route by which the virus crosses between species remains largely unknown. People become infectious once they become symptomatic. Ebola is transmitted via blood or bodily fluid, but can persist outside the body for a couple days. Infection can occur through unprotected contact with the sick, but also when contaminated equipment such as needles cut through healthcare workers’ protective gear, and also through contact with infected individuals postmortem.

David Relman
Photo Credit: Rod Searcey

Ebola’s horrific symptoms provoke public fear, and it becomes easy to lose perspective on the relative spread and toll of this outbreak. Ebola is relatively difficult to transmit. This means the latest Ebola outbreak is still small in comparison to the hundreds of thousands of people killed each year via more easily transmitted airborne influenza strains and other diseases such as malaria and tuberculosis. It’s important that we not lose sight of more chronic, but less headline-grabbing diseases that will be pervasive, insidious long-standing challenges for Africa and elsewhere.

Is there a vaccine or cure?

There is no vaccine for Ebola and no tried-and-true cure. Health workers can only give supportive care to patients and try to stop the spread to new victims.

Several experimental therapies for Ebola are under development. One receiving attention is ZMapp, a mix of antibodies produced by mice exposed to the virus that have been adapted to improve their human compatibility. Limited tests in primates show early promise, but the drug had not been tried on humans -- until now. Two Americans transported back to the U.S. from West Africa received the experimental therapy. While the two seem to be improving, it isn’t clear that ZMapp was responsible; another issue is that ZMapp and other potential therapies have not been cleared by the FDA for wider use in humans.

The process for approval, and who gets priority access to such drugs, are complex policy issues. The WHO will be convening leaders and medical ethicists next week to discuss how to develop and distribute experimental therapies. This is not a simple task; many factors need to be taken into consideration and balanced with limited information to guide decisions.

Successful or not, and despite any approval, it’s still uncertain whether enough of such drugs could even be produced quickly enough to respond to this particular outbreak, and if not - whether they’d be effective in a future outbreak.

 

You can listen to Relman in this KQED Public Radio talk show.

Relman joins other experts in a Stanford panel on Ebola

 

Why has this Ebola outbreak involved so many more people, and spread to a wider geographic area,  than previous outbreaks?

This is an evolving investigation and many potential contributing factors are being examined by scientists racing to collect information that can help them get ahead of the outbreak.

One factor is population density. This latest outbreak spread early into denser population areas within Liberia and Sierra Leone, rather than remain confined to isolated villages, as in earlier outbreaks in Central Africa. With a greater number of people being exposed within a smaller geographic area, the likelihood of transmission increases. Of particular concern is the prospect that the virus might take hold in Lagos, Nigeria, where a handful of cases have been recently identified. If this were to spread in Lagos, Africa’s most populous city, the death toll would likely increase dramatically.   

Another factor is the ability of affected regions to mount an effective public health response. This outbreak is occurring in three of the poorest African countries: Sierra Leone, Liberia, and Guinea. Civil wars have likely contributed to degradation of an already relatively poor public health infrastructure. This is also the first Ebola outbreak in the region, and the inexperience of local authorities can delay responses and fuel fearful community responses, undermining the ability to deal with the outbreak early when it’s more easily contained.

Cultural practices around the care of the sick and the dead can also fuel progression of an outbreak. In some parts of Western Africa, washing deceased relatives is commonplace. Customs like these increase the likelihood of the infection spreading through proximity between infected individuals and their family members

Image
screen shot 2014 08 26 at 1 35 36 pm

 

What can be done to curtail the outbreak?

Isolation and quarantine are key to fighting the spread of Ebola. Isolation involves removing infected individuals from the general population to prevent the spread of disease. Quarantine, however, involves removing uninfected or potentially infected individuals from the general population to limit the spread of disease.

Thus far, the strategy to fight Ebola is dependent on isolating infected patients. Unsurprisingly, isolation efforts have proven hard to enforce. Some families, faced with the prospect of being confined to their homes, have denied the existence of Ebola in their localities, or refuted doctors who claim that one of their family members is sick. This is not unique to Africa; Americans had violent reactions to quarantine during the spread of smallpox. Some regions are now taking more extreme measures: Sierra Leone has deployed its army to enforce isolation at clinics and infected families’ homes, but this also risks civil unrest.

These tensions underscore the necessity of improved education and enforcement mechanisms within public health strategies. Response measures involve fundamental tradeoffs between liberty and safety. Because negotiations occur through complex local, national and international processes, one of the biggest risks is that decisions don’t keep pace with disease spread.

It’s important that we not lose sight of more chronic, but less headline-grabbing diseases that will be pervasive, insidious long-standing challenges for Africa and elsewhere."

How likely is it that the disease will spread into and within the United States?

Currently, airports in Liberia, Sierra Leone, and Guinea are screening all outbound passengers for Ebola symptoms such as fever. This includes asking passengers to complete healthcare questionnaires. However, it is difficult to reliably know who has been infected until they are symptomatic. Individuals could theoretically board a plane before they show symptoms, but develop them upon landing in the United States or elsewhere. This makes containing Ebola difficult, but not impossible.

If the virus were to enter the United States, it would be easier to contain and harder to spread. This virus does not transmit that easily to other humans, especially in settings with good infection control and isolation.

As viruses spread, the chances of genetic variation increase. Yet despite all the concerns from the current outbreak, Ebola is relatively bad at spreading in comparison to respiratory viral diseases such as influenza or measles. The likelihood of a pandemic Ebola virus in the near future seems slim as long as it cannot be transmitted via air.  While it’s possible that the Ebola virus could evolve, there is little evidence to suggest major genetic adaptations at this time.

What are some broader lessons about the dynamics and ecology of emerging infectious diseases that can help prevent or respond to outbreaks now and in the future?

These latest outbreaks remind us that potential pathogens are circulating, replicating and evolving in the environment all the time, and human action can have an immense impact on the emergence and spread of infectious disease.

We are starting to see common factors that may be contributing to the frequency and severity of outbreaks. Increasing human intrusion into zoonotic disease reservoir habitats and natural ecosystems, increasing imbalance and instability at the human-animal-vector interface, and more human population displacement all are likely to increase the chance of outbreaks like Ebola.

Megan Palmer
Photo Credit: Rod Searcey

The epicenter of this latest outbreak was Guéckédou, a village near the Guinean Forest Region. The forest there has been routinely exploited, logged, and neglected over the years, leading to an abysmal ecological status quo. This, in combination with the influx of refugees from conflicts in Guinea, Liberia, Sierra Leone, and Cote d’Ivoire, has compounded the ecological issues in the area, potentially facilitating the spread of Ebola. There seems to be a strong relationship between ecological health and the spread of disease, and this latest outbreak is no exception.

While forensic analyses are ongoing, unregulated food and animal trade in general is also a key factor in the spread of infectious diseases across large geographic regions. Some studies suggest that trade of primates, including great apes, and other animals such as bats, may be responsible for transit of this Ebola strain from Central to Western Africa.

What are some of the other political and security implications of the outbreak and response?

Disease outbreaks can catalyze longer-term political and security issues in addition to more acute tensions.

There are complex international politics involved in emergency response and preparedness. Disease outbreaks often occur in poor regions, and demand help from more wealthy regions. The nature of the response reflects many factors - technical, social, political, legal and economic. Leaders often lack the expertise to take all these factors into account. It is an ongoing challenge to adapt our governance processes to be more reliable and move from damage control to planning. Organizations like the World Health Organization can provide guidance, but more resources and expertise are needed to get ahead of future disasters.

When help is provided, there is often mistrust of non-local workers, who can even be seen as sources of the disease. At a political level, distrust has been fueled by disguising political missions as health interventions, as was the case with the effort that led to the locating of Osama Bin Laden.

There are other security implications of this latest epidemic. This outbreak has led to a dramatic increase in the availability of Ebola virus in unsecured locations across West Africa, as well as to a growing number of labs across the world studying the disease. The immediate need to study the disease and develop beneficial interventions needs to be coupled to considerations of safety and security. From a safety standpoint, a rise in the handling of Ebola samples risks accidental transmission. From a security standpoint, those who wish to cause harm with this virus could acquire it from bodies, graves and other natural sources in the affected region. Both of these risks demand attention and efforts at mitigation.

All News button
1
News Type
News
Date
Paragraphs

CISAC Honors Student Mailyn Fidler has been awarded a Marshall Scholarship to continue her studies in international technology policy. She investigates security implications of the global trade in "zero-day" software exploits. Fidler has also worked as a consultant for Google Glass, autonomous vehicles and Internet access through atmospheric balloons, and was the co-founder and co-editor-in-chief of the Stanford Journal of Public Health.

Marshall Scholarships are named for former U.S. Secretary of State and U.S. Army General George Marshall, and are given to intellectually distinguished Americans to study in Britain.

All News button
1
-

More information TBA. 

 

Speaker bio:

David A. Relman, M.D., is the Thomas C. and Joan M. Merigan Professor in the Departments of Medicine, and of Microbiology and Immunology at Stanford University, and chief of infectious diseases at the Veterans Affairs Palo Alto Health Care System in Palo Alto, California. He is also co-director of the Center for International Security and Cooperation and senior fellow at the Freeman Spogli Institute for International Studies at Stanford University.

Dr. Relman’s primary research focus is the human indigenous microbiota (microbiome), and in particular, the nature and mechanisms of variation in patterns of microbial diversity and function within the human body, and the basis of microbial community resilience. His work was some of the first to employ modern molecular methods in the study of the microbiome, and provided the first in-depth sequence-based analyses of microbial community structure in humans. During the past few decades, his research has included pathogen discovery and the development of new strategies for identifying previously-unrecognized microbial agents of disease. A resulting publication was cited by the American Society for Microbiology as one of the 50 most important papers in microbiology of the twentieth century. He has also served as an advisor to a number of agencies and departments within the U.S. Government on matters pertaining to host-microbe interactions, emerging infectious diseases, and biosecurity. He co-chaired a widely-cited 2006 study by the National Academies of Sciences (NAS) on “Globalization, Biosecurity, and the Future of the Life Sciences”, and served as vice-chair of a 2011 National Academies study of the science underlying the FBI investigation of the 2001 anthrax mailings. He currently serves as a member of the National Science Advisory Board for Biosecurity (2005-), a member of the Committee on Science, Technology, and Law at the National Academy of Science (2012-15), a member of the Science, Technology & Engineering Advisory Panel for Lawrence Livermore National Laboratory (2012-), as Chair of the Forum on Microbial Threats at the Institute of Medicine (NAS) (2007-), and as President of the Infectious Diseases Society of America (2012-2013).

Dr. Relman received an S.B. (Biology) from MIT (1977), M.D. (magna cum laude) from Harvard Medical School (1982), completed his clinical training in internal medicine and infectious diseases at Massachusetts General Hospital, served as a postdoctoral fellow in microbiology at Stanford University, and joined the faculty at Stanford in 1994. He received an NIH Director’s Pioneer Award in 2006, was elected a Fellow of the American Academy of Microbiology in 2003 and the American Association for Advancement of Science in 2010, and was elected a Member of the Institute of Medicine in 2011.

 

 

Reuben W. Hills Conference Room

CISAC
Stanford University
Encina Hall, E209
Stanford, CA 94305-6165

0
Senior Fellow at the Freeman Spogli Institute for International Studies
Thomas C. and Joan M. Merigan Professor
Professor of Medicine
Professor of Microbiology and Immunology
1-RSD13_085_0052a-001.jpg
MD

David A. Relman, M.D., is the Thomas C. and Joan M. Merigan Professor in the Departments of Medicine, and of Microbiology and Immunology at Stanford University, and Chief of Infectious Diseases at the Veterans Affairs Palo Alto Health Care System in Palo Alto, California. He is also Senior Fellow at the Freeman Spogli Institute for International Studies (FSI) at Stanford, and served as science co-director at the Center for International Security and Cooperation at Stanford from 2013-2017. He is currently director of a new Biosecurity Initiative at FSI.

Relman was an early pioneer in the modern study of the human indigenous microbiota. Most recently, his work has focused on human microbial community assembly, and community stability and resilience in the face of disturbance. Ecological theory and predictions are tested in clinical studies with multiple approaches for characterizing the human microbiome. Previous work included the development of molecular methods for identifying novel microbial pathogens, and the subsequent identification of several historically important microbial disease agents. One of his papers was selected as “one of the 50 most important publications of the past century” by the American Society for Microbiology.

Dr. Relman received an S.B. (Biology) from MIT, M.D. from Harvard Medical School, and joined the faculty at Stanford in 1994. He served as vice-chair of the NAS Committee that reviewed the science performed as part of the FBI investigation of the 2001 Anthrax Letters, as a member of the National Science Advisory Board on Biosecurity, and as President of the Infectious Diseases Society of America. He is currently a member of the Intelligence Community Studies Board and the Committee on Science, Technology and the Law, both at the National Academies of Science. He has received an NIH Pioneer Award, an NIH Transformative Research Award, and was elected a member of the National Academy of Medicine in 2011.

Stanford Health Policy Affiliate
CV
David Relman Thomas C. and Joan M. Merigan Professor, Departments of Medicine and of Microbiology and Immunology, Stanford School of Medicine; CISAC Co-Director; FSI Senior Fellow; Stanford Health Policy Affiliate Speaker
Seminars
Subscribe to Public Health